- Trial phase
- Approved
- Time to market
- Already on the market. FDA approved May 2023, EU approved (initial regimen), with the every-four-weeks EU dosing regimen approved March 2026.
- Why 4/10
- Elfabrio is already approved and commercialized in the US and EU with no pending PDUFA or pivotal readout for this drug. The next hard catalyst for Elfabrio itself would be a potential US filing for every-four-weeks dosing, but no submission date has been announced. The stock's next major binary catalyst is PRX-115 Phase 2 topline data in H2 2027, which is a separate pipeline asset. As an approved, marketed drug with commercial execution as the primary driver, Elfabrio scores a 4.
Elfabrio is an approved, revenue-generating drug with growing sales, but the stock's next major binary catalyst is the separate PRX-115 Phase 2 gout readout in H2 2027. For Elfabrio specifically, watch quarterly revenue trends and any announcement of a US filing for the every-four-weeks dosing regimen, which would be a positive catalyst. The Q4 2026 earnings (expected early 2027) will provide the next update on commercial traction.
Price Chart
Executive Summary
Elfabrio (pegunigalsidase alfa) is a PEGylated enzyme replacement therapy for Fabry disease, approved in the US (May 2023), EU, and Canada. It is developed by Protalix BioTherapeutics (PLX) and commercialized by partner Chiesi Global Rare Diseases. The drug competes against Sanofi's Fabrazyme and BioMarin's oral Galafold. Protalix reported strong Q3 2026 results with $21.9M total revenue and $4.0M net income, beating estimates, and management sees a $3.2B Fabry market by 2031 targeting 15-20% market share. The EU approval of every-four-weeks dosing (March 2026) is a competitive differentiator. However, the drug faces headwinds from oral competition (Galafold) and new entrants, and the stock's next major binary catalyst is the separate PRX-115 gout program in H2 2027, not Elfabrio itself.
How It Works
Elfabrio is an enzyme replacement therapy (ERT) for Fabry disease, a rare genetic disorder. Patients with Fabry disease lack a working enzyme called alpha-galactosidase A, causing harmful fats to build up in cells. Elfabrio is a lab-made version of that enzyme, modified with a PEG coating (a common technique to help the drug last longer in the body and reduce immune reactions). It is given as an intravenous infusion every two weeks (or every four weeks for stable patients in the EU) to replace the missing enzyme and clear the fatty buildup.
Trial Status
Elfabrio was approved by the FDA in May 2023 and by the European Commission (initial approval, then an additional every-four-weeks dosing regimen approved March 2026). Health Canada approved it in December 2025. Two Phase 3 open-label extension studies have completed: one for the 1 mg/kg every-2-weeks regimen (97 patients, completed January 2025) and one for the 2 mg/kg every-4-weeks regimen (29 patients, completed April 2026). The Phase 3 BRIGHT study results were published in October 2024.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 / full-year 2026 earnings report (early 2027) showing Elfabrio revenue trajectory
- Potential US FDA filing for every-four-weeks dosing regimen (not yet submitted per March 2026 press release)
- PRX-115 Phase 2 topline data for uncontrolled gout expected H2 2027 (separate pipeline asset)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protalix BioTherapeutics, Inc. 8-K PLX ·Originating report